New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
08:34 EDTPFEPfizer's Bivalent rLP2086 receives FDA Breakthrough Therapy designation
Pfizer announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Pfizer’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 – 25 years of age. Enacted as part of the 2012 FDA Safety and Innovation Act, Breakthrough Therapy designation is intended to expedite the development and review of potential new medicines for serious and life-threatening diseases. A Breakthrough Therapy designation conveys FDA's existing fast track development program features, as well as more intensive FDA guidance on an efficient drug development program. Pfizer is conducting a global clinical development program for rLP2086, which includes both Phase 2 and Phase 3 trials evaluating more than 20K participants, about 14K of whom will receive the investigational vaccine. Following interactions that the company has had with the FDA, Pfizer intends to submit a Biologics License Application to the FDA for bivalent rLP2086 by mid-2014.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
07:33 EDTPFEHospira will not provide annual projections given merger agreement with Pfizer
07:33 EDTPFEHospira expects merger agreement with Pfizer to be completed in 2H15
Subscribe for More Information
07:12 EDTPFEPfizer lowers FY15 adjusted EPS view to $1.95-$2.05 from $2.00-$2.10
Consensus $2.07. Lowers FY15 revenue guidance to $44B-$46B from $44.5B-$46.5B, consensus $45.94B.
07:09 EDTPFEPfizer reports Q1 adjusted EPS 51c, consensus 49c
Subscribe for More Information
April 27, 2015
15:04 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTPFEPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
April 20, 2015
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 15, 2015
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use